ZYVERSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 3.06 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2024-12-31 was 818.50K shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2024-09-30 was 239.30K shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2024-06-30 was 0.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2025 was 3.06M shares, a 140.84% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2024 was 1.27M shares, a 524.98% increase from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2023 was 203.46K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 3.06M shares 10-K · filed 2026-03-31 | ||
| 2025-09-30 | 3.06M shares 10-Q · filed 2025-11-19 | |||
| 2024-12-31 | 818.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 1.06M shares derived: sum of 2 quarters · filed 2025-03-27 | 1.06M shares derived: sum of 3 quarters · filed 2025-03-27 | 1.27M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 239.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 239.30K shares derived: sum of 2 quarters · filed 2024-11-14 | 453.10K shares 10-Q · filed 2024-11-14 | -15.94M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 213.80K shares 10-Q · filed 2024-08-09 | -16.18M shares derived: sum of 3 quarters · filed 2024-08-09 | |
| 2024-03-31 | 213.80K shares 10-Q · filed 2024-05-15 | -16.18M shares derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2023-12-31 | -16.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 203.46K shares 10-K · filed 2024-03-25 | ||
| 2023-09-30 | 16.59M shares 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |